This study could provide critical insights into the role of PDE4B in alcohol use disorder, potentially leading to novel therapeutic approaches. Pharma companies in the mental health space should closely monitor the outcomes for implications on drug development strategies. Regulatory context from MHRA (Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis) supports the near-term read. Assessment grounded in 18 ranked evidence items (11 high-relevance).